PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary OpGen Announces Closing of Public Offering of Common Stock
GAITHERSBURG, Md. , March 29, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc . (Nasdaq: OPGN) announced today the closing of its previously announced underwritten public offering of 9 million shares of its common stock at a public offering price of $0.60 per share. All of the shares were sold by OpGen .
View HTML
Toggle Summary OpGen Data Predicting Antibiotic Resistance Published in Antimicrobial Agents and Chemotherapy Journal
Pivotal data supports use of Acuitas Lighthouse® Software for prediction of antibiotic resistance GAITHERSBURG, Md. , March 28, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN) announced today that data supporting prediction of antibiotic resistance using the company’s Acuitas® AMR Gene Panel
View HTML
Toggle Summary OpGen Announces Pricing of a $5.4 Million Public Offering of Common Stock
GAITHERSBURG, Md. , March 26, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc . (Nasdaq: OPGN) announced today the pricing of an underwritten public offering of 9 million shares of its common stock at a public offering price of $0.60 per share. The company also granted the underwriters a 45-day option to
View HTML
Toggle Summary OpGen and Merck’s ILÚM Health Solutions to Host Event at VIII International Symposium on Hospital Acquired Infections and Antimicrobial Stewardship
GAITHERSBURG, Md. , March 25, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc . (Nasdaq: OPGN) announced today it will host an event with ILÚM Health Solutions, LLC (“ILÚM”), a wholly owned subsidiary of Merck’s Healthcare Services and Solutions, at the VIII International Symposium on Hospital Acquired
View HTML
Toggle Summary OpGen Reports Fourth Quarter and 2018 Financial Results and Provides Business Update
Conference call begins at 4:30 p.m. Eastern time today GAITHERSBURG, Md. , Feb. 26, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) today reported financial and operating results for the three and 12 months ended December 31, 2018 and provided a business update.
View HTML
Toggle Summary OpGen Appoints R. Don Elsey to Board of Directors
GAITHERSBURG, Md. , Feb. 25, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) announces the appointment R. Don Elsey to the company’s board of directors and audit committee, effective February 21 , 2019.  He will serve as chairman of the board’s audit committee and will stand for reelection for
View HTML
Toggle Summary OpGen Announces Date of Fourth Quarter and Fiscal Year 2018 Financial Results Conference Call
GAITHERSBURG, Md. , Feb. 20, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) announced today that the Company will report its fourth quarter and fiscal year 2018 financial results after the close of the U.S. financial markets on Tuesday, February 26, 2019 .
View HTML
Toggle Summary OpGen Completes Clinical Trials for its Initial FDA 510(k) Submission
GAITHERSBURG, Md. , Feb. 05, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN) announced today that it has completed the clinical trials needed to support its 510(k) submission for the detection of antimicrobial resistance genes in bacterial isolates to the U.S.
View HTML
Toggle Summary OpGen Completes CDC Contract to Develop Clinical Support Mobile-Based Tools for Antimicrobial Stewardship and Infection Control
GAITHERSBURG, Md. , Dec. 18, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) today announced that it has provided the final report for completion of the contract from the Centers for Disease Control and Prevention (CDC) to develop smartphone-based clinical decision support solutions for
View HTML
Toggle Summary OpGen Receives Regulatory Approval to Market Pathogen Identification Products in Colombia
Approval gives OpGen its first commercial product in the region; paves way for broader expansion into South American markets GAITHERSBURG, Md. , Dec. 04, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN) announced today it has received approval from the Instituto Nacional de Vigilancia de
View HTML